T2 biosystems announces exclusive u.s. agreement with cardinal health to sell its fda-cleared direct-from-blood diagnostics for rapid detection of sepsis-causing pathogens

Lexington, mass., oct. 07, 2024 (globe newswire) -- t2 biosystems, inc. (nasdaq: ttoo) (the “company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has entered into a multi-year exclusive u.s. agreement with cardinal health (nyse: cah),. under the agreement, cardinal health will have exclusive rights to sell t2 biosystems' fda-cleared direct-from-blood diagnostics for the rapid detection of sepsis-causing pathogens, including the t2dx® instrument, the t2bacteria® panel, and the t2candida® panel.
CAH Ratings Summary
CAH Quant Ranking